Abata Therapeutics

Director, Computer System Validation - Quality Assurance (CSV QA)

Remote

Not SpecifiedCompensation
Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
BiotechnologyIndustries

Position Overview

  • Location Type: Remote
  • Employment Type: Full-time
  • Salary: Not specified

About Apogee Therapeutics:

Apogee Therapeutics, Inc. (Ticker: APGE) is a well-funded, Nasdaq listed biotechnology company founded in 2022. It is seeking to develop differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications with high unmet need. Apogee is committed to building an exceptional company culture based on its C.O.R.E. values: Caring, Original, Resilient, and Egoless.

Role Summary

Apogee Therapeutics is seeking a Director of Computer System Validation (CSV) Quality Assurance (QA) to provide strategic leadership and oversight of the validation of GXP computer systems and software. This role will drive the development, execution, and continuous improvement of CSV and Computer Software Assurance (CSA) processes, ensuring systems are validated, maintained, and compliant with regulatory standards.

Key Responsibilities

  • Lead and manage the CSV QA function, ensuring GXP computer systems are validated in compliance with relevant regulatory requirements.
  • Develop and implement CSV strategies, policies, and processes to ensure consistent, scalable, and efficient validation across the organization.
  • Oversee the planning, execution, and documentation of validation activities for new and existing GXP computer systems, ensuring compliance throughout their software development lifecycle (SDLC).
  • Collaborate cross-functionally with IT, software development, regulatory affairs, and other departments to ensure seamless integration of validated systems into business operations.
  • Lead efforts to identify, assess, and mitigate risks related to computer systems, ensuring potential issues are proactively addressed.
  • Drive improvements in CSV and data integrity processes and methodologies, introducing innovative solutions and best practices, including CSA principles, to enhance efficiency and ensure scalability.
  • Ensure validation documentation (validation plans, test scripts, reports, risk assessments, etc.) is maintained in compliance with regulatory requirements.

Requirements

  • (No specific requirements listed in the provided text)

Application Instructions

  • (No application instructions provided in the text)

Skills

Computer System Validation
CSV
GXP
Validation Strategies
Regulatory Compliance
SDLC
Risk Assessment
Data Integrity
Process Improvement
Cross-functional Collaboration

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Cambridge, MassachusettsHeadquarters
2021Year Founded
$184.8MTotal Funding
EARLY_VCCompany Stage
BiotechnologyIndustries
11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.
Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.
Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.
Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.
Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.
FDA's accelerated approval pathways may expedite Abata's clinical trials.
Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI